Non-scheduled anti-cancer medicines to face 30% trade-margin cap

The government has approved a 30%-of-MRP trade-margin cap on non-scheduled anti-cancer medicines, projecting price reductions of up to 70% and annual patient savings of ₹2,500 crore. A DGHS committee will finalise coverage before NPPA notification.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.